Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus CNCM I-4036
- Development stage
- Unknown
- Lead developer
- Archer Daniels Midland
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus CNCM I-4036 is a probiotic bacterial strain originally isolated from the feces of exclusively breast-fed infants. It was characterized and developed by researchers at the University of Granada in collaboration with the Hero Group. The strain demonstrates significant immunomodulatory and anti-inflammatory properties, including the ability to modulate macrophage gene expression and reduce pro-inflammatory cytokines such as IL-12 while increasing anti-inflammatory markers like IL-10. In preclinical models, it has shown efficacy in reducing hepatic steatosis and lowering serum lipopolysaccharide (LPS) levels in obese Zucker rats. Clinical studies in healthy adults and athletes have evaluated its safety, intestinal colonization, and effects on the immune system and stress parameters. It is often formulated as part of synbiotic mixtures, such as Gasteel Plus, for gastrointestinal and immune health.
- Brand names
- Gasteel Plus
- Other names
- Lactobacillus rhamnosus CNCM I-4036Lr
02
Targets
TLR2 (Toll-like Receptor 2)IL10 (Interleukin-10)TLR1TLR5TLR9 (Toll-like receptor 9)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on lactobacillus rhamnosus CNCM I-4036.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus CNCM I-4036.